Uses
A pyrrolyl benzoic acid that effectively competes against ephrin-B3 for EphA4 binding as well as against ephrin-A1/-A2/-A3/-A5 for EphA2 and EphA4 binding by targeting EphA2/A4 high affinity ephrin-binding pocket in a reversible manner (
Ki = 6-10 and 11-14 µM against ephrin-A5 binding to EphA4 and EphA2, respectively), exhibiting much reduced or no potency against ephrin-A4 for EphA2/EphA4 binding, ephrin-A5 for EphA3/A5/A6/A7 binding, ephrin-B2 for B1/B2/B3/B4/B6 binding, or ephrin-B2 for EphA4 binding. Shown to inhibit 0.1 µg/mL ephrin-A1-Fc fusion-induced EphA2 phosphorylation in COS7 (by 92% at 200 µM) and 0.5 µg/mL ephrin-A5-Fc fusion-induced EphA4 phosphorylation in HT22 neuronal cultures (by 42% and 79% respectively, at 300 and 400 µM) without any cytotoxicity (up to 400 µM and 3 days in HT22 cultures). Also effective toward chicken and zebrafish EphA4 orthologs as evidenced by its efficacy in preventing 1 µg/mL ephrin-A5-Fc-induced growth cone collapse of neurons in 6-d chicken embryo retina (by 100% at 400 µM)
ex vivo and in fully rescuing human mutant SOD-1 A4V transgene-induced axonopathy in zebrafish embryos (500 µM; treatment period from 6 to 30 hpf)
in vivo.
